Sandstone Diagnostics Raises $5.8M in Series A1 Funding

Sandstone Diagnostics, a Livermore, CA-based medical device company focused on a data-driven approach to men’s reproductive health, held the first closing of $5.8m of its Series A1 round including conversion of notes.

The round was led by Astia Angels and Hunt Holdings, along with a consortium of investors including DPW Holdings (NYSE:DPW).

The company will use the funds for sales growth and continued product development.

Founded in 2012 in part by government scientists from Sandia National Laboratories an led by CEO Karen Drexler, Sandstone provides the Trak™ Male Fertility Testing System, an FDA-cleared, consumer device that lowers fertility testing barriers and allows men to take control of their reproductive health. Men use the Trak device at home along with the Trak mobile app to test, learn and try to improve their sperm count so couples can improve odds of conception.
The Trak app gathers key lifestyle data and uses proprietary algorithms built with urologists to give targeted feedback on how health and habits may impact men’s fertility.



Join the discussion